ALLR — Allarity Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1860657 ·
Last close
$1.68
Market Cap
$26.81M
52W High
$1.78
52W Low
$0.95
ADV30
219,460
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 25,000 | — | -2,688,000 | -2,750,000 | 34,923,000 | 19,812,000 | 28,003,000 |
| Dec 2025 | 320,000 | — | -2,918,000 | -3,373,000 | 18,258,000 | 14,687,000 | 8,430,000 |
| Sep 2025 | 0 | — | -2,518,000 | -2,806,000 | 20,796,000 | 16,895,000 | 8,785,000 |
| Jun 2025 | 0 | — | -4,133,000 | -2,320,000 | 21,205,000 | 17,801,000 | 9,038,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-14,820,000
Investing CF
—
Financing CF
$10,648,000
CapEx
—
Dividends Paid
—
Buybacks
$-4,125,000
EPS Diluted TTM
$-8.30
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-130,197,000
Inventory
—
Receivables
$895,000
ST Investments
—
EBIT TTM
$-11,046,000
Pretax Income TTM
$-11,231,000
Interest Exp TTM
$185,000
Analysts
1
Yahoo Snapshot (yfinance, live)
Total Revenue
$320,000
EBITDA
$-12,596,000
Free Cash Flow
$-10,213,750
Enterprise Value
$7,985,623
Total Cash
$14,770,000
Total Debt
$1,400,000
Shares Out
15,910,724
Trailing EPS
$-0.70
Book Value
$0.52
ROE
-103.8%
ROA
-38.5%
Div Yield
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 320,000 | -12,605,000 | -11,231,000 | 18,258,000 | 8,430,000 | — | -14,820,000 |
| Dec 2024 | 0 | -17,538,000 | -24,515,000 | 22,650,000 | 10,839,000 | — | -17,352,000 |
| Dec 2023 | 0 | -17,129,000 | -11,901,000 | 11,862,000 | 14,613,000 | — | -12,745,000 |
| Dec 2022 | 0 | -16,892,000 | -16,058,000 | 14,544,000 | 12,654,000 | — | -16,817,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.97
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| OTLC | Oncotelic Therapeutics, Inc. | $26.67M | $0.06 | — |
| RMHI | Retrieve Medical Holdings, Inc. | $27.18M | $1.00 | — |
| TPST | Tempest Therapeutics, Inc. | $26.21M | $1.77 | — |
| MDNAF | Medicenna Therapeutics Corp. | $26.14M | $0.31 | — |
| CELU | Celularity Inc | $25.96M | $0.90 | — |
News headlines (Yahoo Finance, 1h cache)
Are Medical Stocks Lagging Bioventus (BVS) This Year?
2026-05-18 13:40 · Yahoo
Allarity Therapeutics Reports First Quarter 2026 Results and Continued Stenoparib Development in Multiple Cancers
2026-05-15 20:30 · Yahoo
Allarity Therapeutics CEO to Present at Precision Medicine Forum Europe 2026 in Stockholm
2026-05-08 12:45 · Yahoo
Allarity Therapeutics Advances Stenoparib Toward Pivotal Development with Phase 3 Manufacturing Campaign
2026-05-05 12:00 · Yahoo
Allarity Therapeutics Announces that the Stenoparib DRP® Test Has Received a Notice of Allowance from the US Patent and Trademark Office
2026-04-27 12:00 · Yahoo
Allarity Therapeutics Presents Two AACR 2026 Posters Highlighting Stenoparib’s Potential in Colorectal Cancer as well as New Predictive Data Linking DRP® and Overall Survival in Ovarian Cancer
2026-04-21 12:00 · Yahoo
Allarity Therapeutics Reports Full Year 2025 Financial Results and Corporate Progress
2026-03-31 12:00 · Yahoo
Allarity closes $20M financing for stenoparib advancement
2026-03-07 13:19 · Yahoo
Allarity Therapeutics Closes $20 Million Financing to Accelerate the Advance of Stenoparib Toward FDA Approval and Commercialization
2026-03-06 13:00 · Yahoo
Allarity Therapeutics Doses First Patients in VA-Funded Phase 2 Trial Focused on Small Cell Lung Cancer with High Unmet Need
2026-02-18 13:15 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.